Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the closing of its previously announced underwritten registered direct offering which included the issuance of 1,800,000 shares of its common stock at a price of $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares of common stock at a price of $2.9199 per pre-funded warrant. The gross proceeds to the Company from the offering are approximately $55 million, before deducting underwriting discounts and commissions and other offering expenses pay

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the pricing of a $55 million registered offering. Tharimmune, Inc. operates a differentiated digital asset treasury strategy by actively participating in the Canton Network – a privacy-enabled, secure blockchain hosting trillions in assets on chain. The offering is expected to close on or about January 21, 2026, subject to the satisfaction of customary closing conditions. The transaction includes the issuance of 1,800,000 shares of its common stock at a price of $2.

Milestone Underscores Accelerating Institutional Adoption of Blockchain Technology and Aligns with Tharimmune's Canton Coin Treasury Strategy NEW YORK, Dec. 18, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today issued commentary following the Depository Trust & Clearing Corporation's ("DTCC") announcement of its partnership with Digital Asset Holdings to tokenize U.S. Treasury securities custodied at DTCC on the Canton Network. Mark Wendland, CEO of Tharimmune, commented: "DTCC's announcement represents another meaningful step in the structura

Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial reporting, and the continued expansion of Tharimmune's CC treasury infrastructure. Mr. Asbury brings nearly two d

RED BANK, N.J., Nov. 13, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a digital asset treasury company with a clinical-stage biotechnology function, today announced an update from the biotechnology side of the business. Its lead clinical asset, TH104 (nalmefene buccal film), received positive feedback from the U.S. Food and Drug Administration (FDA) on the Company's submitted simulation modeling plan. Tharimmune announced earlier this month its plans to develop a digital asset treasury strategy that leverages the Canton Coin to support the Canton Network's ability to digitize traditional financial markets. In a formal Type D meeting with the FDA, Thar

Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT Strategy Net Proceeds Support Acquisition of Canton Coin and Active Network Participation via Validator Infrastructure and Application Development NEW YORK, Nov. 6, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a publicly traded company that will leverage the Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the successful close of its previously announced private placement for the purchase and sale of shares of common stock (or par-value pre-funded warrants in lieu

 Other Participants Include ARK Invest, Bitwave, Broadridge, Clear Street, Copper, Digital Asset, Feynman Point Asset Management, Five North, Kaiko, Kenetic, Kraken, LendOS, Lukka, Nima Capital, MPCH, Obsidian Software, Polychain Capital, Proof Group, SBI Group, The Tie, Tradeweb Markets, and 7RIDGECanton Foundation, Governing Body Overseeing the Canton Network, Participates in the TransactionCompany Will Offer Investors Diversified Value Stream Via Next-Gen DAT Strategy Aligned with Differentiated Vehicle Designed Specifically for Institutional Blockchain AdoptionNEW YORK, Nov. 3, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company") today announced that it has

RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences. The Tharimmune team will present new results at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 24-29, 2025 at the Phoenix Convention Center in Phoenix, AZ; and the American Association for the Study of Liver Diseases (AASLD) Annual Conference, The Liver Meeting® 2025 to be held November 7 -10, 2025, in Washington, DC; as w